Nouvelle déclaration d'incident
No de la demande: 2009-1588
Numéro de référence du titulaire d'homologation: Prosar case 1-16000959
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: BRITISH COLUMBIA
ARLA No d'homologation 26491 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Control Pet Care System One Spot Topical Treatment for Cats and Kitten
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Cat / Chat
Domestic Shorthair
1
Femme
6
Inconnu
Cutanée
Unknown / Inconnu
>8 hrs <=24 hrs / > 8 h < = 24 h
Système
Anticip. permanent/Permanence anticipée
Oui
Oui
Inconnu
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
1-16000959: The reporter called on 4/10/08 to report her 6 year old female cat was paralyzed less than 24 hours after she had applied a topical flea and tick product containing the active ingredient Methoprene. She had applied the product to her cat the previous night, and noticed some funny meowing. The next morning the cat was paralyzed in its hind legs. The reporter had an appointment scheduled that day with her veterinarian, but wondered if there was anything she could do in the meantime. She was advised to try and wash the product off with tepid water and hand dish soap, and to take the cat into the veterinarian. Later that same day, the attending veterinarian called to discuss the safety profile of the product. She had diagnosed the cat with an aortic thromboembolism due to its classic clinical signs - bilateral hind leg paralysis, lack of femoral pulses, cold body temperature, pale mucous membranes, and pain. However, she wanted to verify that the symptoms could not be caused by the product. The safety profile of the product was discussed. The attending veterinarian was assured that paralysis or paresis was not part of the product's toxic syndrome, which would typically include ataxia, tremors, and seizures. A recommendation was made to perform an echocardiogram, and to try low-dose molecular weight heparin and cardiac medications as needed to treat the thromboembolism and manage any underlying cardiac disease. The reporter called back later in the day on 4/10/08 with a request for further information about the toxic profile of the product. Information regarding the typical toxicosis of the product was given. The reporter was also assured that paralysis was not part of the product's toxic syndrome, and was encouraged to work with her veterinarian looking into other differentials for the paralysis.
Majeure